REG - Feedback PLC - Director/PDMR Shareholding

FeedbackAnnouncement

02/12/2021 10:25

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20211202:nRSB3698Ua&default-theme=true

RNS Number : 3698U  Feedback PLC  02 December 2021

Feedback plc

Director Dealings

London, UK, 02 December 2021   - Feedback plc (AIM: FDBK, "Feedback" or the
"Company"), the specialist clinical communication company, announces that
further to the Fundraising, details of which were announced on 2 November 2021
and Admission which occurred on 30 November 2021, the following Directors'
dealings as part of the Placing and Open Offer have completed:

Rory Shaw, Non Executive Chairman, has subscribed for 1,441,859 New Ordinary
Shares through the Open Offer at the Issue Price of 0.7 pence per Ordinary
Share.

Philipp Prince, Non Executive Director, has subscribed for 1,546,543 New
Ordinary Shares through the Open Offer at the Issue Price of 0.7 pence per
Ordinary Share.

Adam Denning, Non-Executive Director, has subscribed for 1,428,570 New
Ordinary Shares through the Placing at the Issue Price of 0.7 pence per
Ordinary Share.

Details of the Ordinary Shares held by these Directors are detailed in the
table below:

 Director/ PDMR  Position                Existing interest in Ordinary Shares  Ordinary Shares purchased  Total beneficial interest in Ordinary Shares  Total interest in Company's issued share capital
 Rory Shaw       Non-Executive Chairman  9,818,780                             1,441,859                  11,260,639                                    0.4%
 Philipp Prince  Non-Executive Director  2,500,000                             1,546,543                  4,046,543                                     0.2%
 Adam Denning    Non-Executive Director  1,530,411                             1,428,570                  2,958,981                                     0.1%

 

The notification set out below, provides further details of such dealings:

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Names                                                        Rory Shaw

                                                                   Philipp Prince

                                                                   Adam Denning
 2    Reason for the notification

 a)   Position/status                                              Non-Executive Chairman

                                                                   Non-Executive Director

                                                                   Non-Executive Director
 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Feedback plc

 b)   LEI                                                          213800UGOF2GT2U2RV90

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary Shares of 0.25 pence each in Feedback plc

      Identification code                                          GB0003340550

 b)   Nature of the transaction                                    Purchase of Ordinary Shares

 c)   Price(s) and volume(s)

                                                                                     Price(s)          Volume(s)
                                                                                     0.7p              1,441,859
                                                                                     0.7p              1,546,543
                                                                                     0.7p              1,428,570

 d)   Aggregated information

      - Aggregated volume                                          n/a

      - Price

 e)   Date of the transaction                                      30 November 2021

 f)   Place of the transaction                                     XLON

 

The capitalised terms used in this announcement have the same meanings as in
the announcement published by the Company at 7.01 a.m.  on 2 November 2021
unless otherwise stated.

Enquiries:

 

 Feedback plc                                    +44 (0)1954 718072

 Tom Oakley, CEO                                 IR@fbk.com (mailto:IR@fbk.com)

 Anesh Patel, CFO

 Panmure Gordon (UK) Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Freddy Crossley (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd                                 Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                                 (mailto:feedbackplc@walbrookpr.com)
 Paul McManus/Nick Rome/Nicholas Johnson         07980 541 893 or 07748 325 236 or 07884 664 686

 

Notes to Editors

 

Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication
products. Its core product, Bleepa, is a revolutionary medical imaging
communications app, providing an easy-to-use, high quality tool to enable
remote and secure communications between front-line clinicians and teams.
Importantly, it is the only CE marked medical imaging communications platform
on the NHSx clinical communications tools framework. Bleepa has unparalleled
functionality for everyday practice and can be accessed from any
internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will
provide increasing levels of visibility as the Company grows its customer
base. With a growing distribution base and technology in place, the focus is
on leveraging key relationships in order to drive sales both in the UK and
internationally to all forms of care providers. As a fully certified medical
device, Bleepa aims to disrupt the medical imaging communications market and,
importantly, increase the accuracy and speed of clinical review.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHUPGRGPUPGGUP